Efficacy and safety of 153Sm-EDTMP as treatment of painful bone metastasis: a large single-center study.

The purpose of this study is to assess the efficacy of 153Sm-EDTMP (Quadramet®) in a clinical setting.
We have conducted a retrospective study of all consecutive patients (pts) treated with 153Sm-EDTMP for painful bone metastases. At each visit (before and after treatment), four parameters were collected: (i) pain assessment according to the 10-step visual analogue scale (VAS), (ii) sleep disturbance related to pain, (iii) dose of analgesic medication, and (iv) answer to the following closed question "Do you think you obtained a benefit from treatment?" Success of treatment was defined by the combination of these four parameters.
Three hundred seventy consecutive 153Sm-EDTMP treatments for painful bone metastases were given. Patients had the following primary tumors: breast carcinoma (153), prostate carcinoma (155), lung carcinoma (27), or other cancers (35). Fifty-eight percent of the patients had received previous external osseous radiotherapy. Ninety-seven percent of the patients were treated with concomitant analgesics and 61% were treated with diphosphonates. A clinical benefit was described in 55.0% of cases at D30. Treatment was more effective in cases of breast and prostate cancers compared with other types of primary cancers. Patients described a benefit at D30 in 62, 58, 6, and 38% of cases of breast, prostate, lung, and other cancers. The subjective efficacy was accompanied by a decrease in analgesic intake in 35.0% of cases.
153Sm-EDTMP therapy is an effective supportive treatment in patients who suffer from bone metastases, especially in patients with breast or prostate cancer.
AuthorsHélène Kolesnikov-Gauthier, Nathalie Lemoine, Emmanuelle Tresch-Bruneel, Anaïs Olivier, Aurore Oudoux, Nicolas Penel
JournalSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (Support Care Cancer) Vol. 26 Issue 3 Pg. 751-758 (Mar 2018) ISSN: 1433-7339 [Electronic] Germany
PMID28920149 (Publication Type: Journal Article)
Chemical References
  • Radioisotopes
  • Samarium
  • Samarium-153
  • Adult
  • Aged
  • Aged, 80 and over
  • Bone Neoplasms (drug therapy, secondary)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pain (drug therapy)
  • Radioisotopes (pharmacology, therapeutic use)
  • Retrospective Studies
  • Samarium (pharmacology, therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!

Choose Username:
Verify Password:
Enter Code Shown: